Michèle Barzach

Corporate Officer/Principal at International AIDS Vaccine Initiative, Inc.

Health Technology

Profile

Michèle Barzach is currently the Director-Emeritus at the International AIDS Vaccine Initiative, Inc. She previously worked as a Non-Executive Director at GSK Plc from 1997 to 2004.

Michèle Barzach active positions

Companies	Position	Start
International AIDS Vaccine Initiative, Inc. International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.	Corporate Officer/Principal	2010-11-29

All active positions of Michèle Barzach

Former positions of Michèle Barzach

Companies	Position	End
GSK PLC	Director/Board Member	2004-05-16

See the detail of Michèle Barzach's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michèle Barzach's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
GSK PLC	Health Technology

Private companies	1
International AIDS Vaccine Initiative, Inc. International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.	Health Technology